Heather Wakelee, MD, and Helena Yu, MD, discuss how they approach patient selection for osimertinib monotherapy vs combination therapy in 2026.
Back
Optimizing Sequencing in EGFR-Mutant Advanced NSCLC
Heather Wakelee, MD, and Helena Yu, MD, discuss sequencing strategies in EGFR-mutant NSCLC, including frontline choices, resistance, and emerging targeted therapies.
Optimizing Sequencing in EGFR-Mutant Advanced NSCLC
Episodes
All
All
Heather Wakelee, MD, and Helena Yu, MD, examine how FLAURA2 and emerging post-progression data inform sequencing decisions.
Heather Wakelee, MD, and Helena Yu, MD, discuss when chemotherapy rechallenge may be appropriate in EGFR-mutant NSCLC.
Heather Wakelee, MD, and Helena Yu, MD, discuss how TP53 and other co-mutations influence prognosis and sequencing decisions.
Heather Wakelee, MD, and Helena Yu, MD, discuss how ADCs are being incorporated into sequencing strategies after osimertinib.
Heather Wakelee, MD, and Helena Yu, MD, discuss how to plan long-term treatment sequencing from the time of diagnosis.
Heather Wakelee, MD, and Helena Yu, MD, discuss emerging biomarkers and key evidence gaps in EGFR-mutant NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
OncLive Weekly News Quiz (8/14/2026): Did You Catch This Week's Myeloma, Lung Cancer, and Polycythemia Vera Updates?
5